Post Profile






Mavenclad Reduces MS Relapses by Reseting the Immune System

New analyses of how Merck’s Mavenclad (cladribine tablets) act to treat relapsing multiple sclerosis (MS) give researchers an entirely new picture of immune processes leading to the disease. Data showed that the drug lowers both immune B-cells and, to a lesser degree, T-cells. But the numbers of both cell types are back to normal by […] The post Mavenclad Reduces MS Relapses by Reseting the Immune System appeared first on Multiple Sclerosis News Today.
read more

share

Related Posts


Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Merck has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients with relapsing-remitting multiple sclerosis (RR...

Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients with relapsing multiple sclerosis (RMS) has reduced the disease’s annualized relapse rate (ARR), researchers reported. Leading the P...

Cladribine Tablets Reduce Risk of MS Progression and Relapse, Clinical Trial Shows

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also well-tolerated and had a good safety profile, ...

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended...

#CMSC17 – Cladribine Reduced Annual MS Relapse Rate by 55% to 57%, Trials Show

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, according to clinical trials. EMD Serono, a unit of Cladribine’s developer, Merck, presented the trial...

Comments


Copyright © 2016 Regator, LLC